| Ytd | 28.77% | |
| 1y | 71.95% |
| Open | Prev Close | 2.82 | Low | High | Mkt Cap | 459.81M | |||
| Vol | 0.00 | Avg Vol | 5.01M | EPS | -1.96 | P/E | -1.44 | Forward P/E | -0.98 |
| Beta | 3.26 | Short Ratio | 4.26 | Inst. Own | 100.47% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 3.22 | 200-d Avg | 2.85 | 1yr Est | 22.22 |
CABA News
Cabaletta Bio (CABA) offers a de-risked, breadth-first CAR-T platform for autoimmune diseases, with
Cabaletta Bio, Inc. (CABA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 T
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registratio
83% of dermatomyositis patients in the Phase 1/2 RESET-Myositis study would have met the registratio
Here is how Cabaletta Bio, Inc. (CABA) and Curaleaf Holdings, Inc. (CURLF) have performed compared t
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t
Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Equal-Weight and r
Cabaletta Bio, Inc. is reaffirmed as a Buy despite recent share price volatility, driven by tangible
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.39) per share which met the analyst con
Preconditioning-free (PC-free) 6-to-9-month clinical data with a single infusion of the lowest dose
A single infusion of the lowest dose of rese-cel administered without preconditioning, after discont
Global Business Travel Group Inc (GBTG), a NYSE-listed company, saw its stock rise 57% on Monday af
Cantor Fitzgerald analyst Josh Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight
Cabaletta Bio, Inc. ("Cabaletta" or the "Company") (NASDAQ:CABA), a clinical-stage b
PHILADELPHIA, May 04, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (“Cabaletta” or the “Company”) (N
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac
Agreement facilitates flexible, scalable automated industrialized production of rese-cel for many th
PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cl
First two GMP doses of rese-cel manufactured on the Cell Shuttle™ met all release specifications, we
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufac
Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29
Analysts change ratings & price targets for HSCS, ONDS, STRO, PFE, HST, CABA, INSM, PVH. See ful
Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lo
Guggenheim analyst Yatin Suneja maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the p
Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.40) per share which beat the analyst co
Rese-cel myositis BLA submission on track for 2027 based on a 17-patient, single arm registrational
Cabaletta Bio (NASDAQ: CABA) used a fireside chat at TD Cowen's 46th Annual Health Care Conference t
Cabaletta Bio (CABA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about t
PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cli
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage cli
Does Cabaletta Bio, Inc. (CABA) have what it takes to be a top stock pick for momentum investors? Le
On Thursday, 1076 companies hit new 52-week lows.
Wednesday's session saw 269 companies set new 52-week lows.
During Monday's trading, 1214 companies set new 52-week lows.
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday